BeyondSpring is trading 5.01% up at $0.81, with the cause of the October 1 move unclear.
- No clear company-specific catalyst for the move was identified.
- The latest located company announcement, dated September 29, covered FDA Fast Track designation for plinabulin and a strategic transaction. It predates this session and does not establish the reason for the gain.
- The broader market was mixed, with the supplied major-index moves below 0.5%; available evidence does not point to a broad-market driver.